Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Inv Nylon Chemicals Americas LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners but are both located within 1 distinct art unit. RODRIGUEZ-GARCIA, VALERIE is the busiest examiner, currently managing 1 pending office action. The 2 pending office actions are concentrated in 1 distinct art unit, which suggests a specific technical focus for the company's chemical innovations.
Although the actions are in the same 1 distinct art unit, they are assigned to 2 distinct examiners. RODRIGUEZ-GARCIA, VALERIE is responsible for 1 of the 2 pending actions. This distribution means that while the technical field is narrow, the company must manage two different examiner perspectives. The presence of 2 distinct examiners for only 2 actions ensures that each matter receives individual attention. Practitioners should focus on maintaining consistency across these 2 pending office actions despite the different examiners involved in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864004 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | ELENISTE, PIERRE PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18995166 | PROCESSES FOR PRODUCING NITRILES AND PHOSPHORUS-CONTAINING CATALYSTS FOR USE IN SUCH PROCESSES | RODRIGUEZ-GARCIA, VALERIE | — |
| 18864004 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | ELENISTE, PIERRE PAUL | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18995166 | PROCESSES FOR PRODUCING NITRILES AND PHOSPHORUS-CONTAINING CATALYSTS FOR USE IN SUCH PROCESSES | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103 | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18864004 | MULTIDENTATE PHOSPHITE LIGANDS, CATALYTIC COMPOSITIONS CONTAINING SUCH LIGANDS, AND CATALYTIC PROCESSES UTILIZING SUCH CATALYTIC COMPOSITIONS | ELENISTE, PIERRE PAUL | — | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInv Nylon Chemicals Americas LLC has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Inv Nylon Chemicals Americas LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
